

## Tegsedi<sup>®</sup> (inotersen) Medication Precertification Request

Page 1 of 1

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification Phone: 1-866-752-7021 (TTY: 711)

FAX: <u>1-888-267-3277</u>

For Medicare Advantage Part B: Please Use Medicare Request Form

Please indicate:			of last treatment	1 1					
		• •	Or last treatment	<del></del>		Ган			
Precertification Re				Phone:		Fax:			
A. PATIENT INFOR	RIMATION		Last Name:			DOB:		<u> </u>	
			Last Name.	Cit.		DOB:	ZIP:		
Address:		W. J. Di		City:		State:	ZIP:		
Home Phone:	<del></del>	Work Phone:		Cell Phone:		Email:			
Current Weight:		kgs Height:	inches orcr	ns Allergies:					
B. INSURANCE IN					s 🗌 No				
Aetna Member ID #:			_ Does patient have other						
Group #: nsured:			If yes, provide ID#: Carrier Name: Insured:						
Medicare:  Yes	□ No If yes pro	vide ID #:		dicaid: Yes No	If yes nrov	ide ID #·			
C. PRESCRIBER II		vide ID #.	MC	uicaia: 103 110	ii yes, piev	ide ib #.			
First Name:	NI OKWATION		Last Name:	(	Check One:	Пм.р. П	D.O.	ПРА	
Address:				City:		State:	ZIP:		
Phone:	Fax:		St Lic #:	NPI #:	DEA #:	0.0.0.	UPIN:		
Provider Email:	ı ax.		Office Contact Name:	1	DEATH.	Phone:	0		
Specialty (Check on	e):   Neurologis:	t				1			
	<u> </u>								
D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION  Place of Administration:  ☐ Self-administered ☐ Physician's Office				Dispensing Provider/Pharmacy: (Patient selected choice)  ☐ Physician's Office ☐ Retail Pharmacy					
☐ Outpatient Infusio	-			☐ Specialty Pharmacy ☐ Other:					
	ne:			Name:					
				Address:					
Agency Nar  Administration co	ne:			Phone:					
Address:				TIN:					
E. PRODUCT INFO									
Request is for: Tegs		ose.		Frequency:					
			ary ICD code and specif		cable				
		acc malcate prim	ary 102 oodo and opcom	Other ICD Code:					
Primary ICD Code: Other ICD Code:  G. CLINICAL INFORMATION - Required clinical information must be completed in its entirety for all precertification reque									
For All Requests (	·		·	ed in its <u>entirety</u> for all pr	ecerimeanor	rrequests.			
			: ed amyloidosis (transtl	ovretin-type familial an	nyloid nolyr	neuronathy [	ΔTTR-FΔP1)		
	=	-	ction of a mutation in the		nyiola polyi	iouroputity [	,A		
	_	•	estations of polyneuropa	•	yretin-media	ted amyloido:	sis (ATTR-FAP)		
, ,			ecimens, TTR protein vai			-		athy)?	
tran	nsthyretin-mediate	d amyloidosis (e	d in combination with any .g., Amvuttra, Onpattro, '	Vyndamax, Vyndaqel, W	/ainua)?		•		
	☐ Yes ☐ No Will the requested medication be prescribed by or in consultation with any of the following: a) Neurologist, b) Geneticist, or c) Physician specializing in the treatment of amyloidosis?								
,	, ,	· ·	equired for all requests)	:					
neu cor	uropathy severity a	and rate of diseas Norfolk Quality o	icial response to the requese progression as demor of Life-Diabetic Neuropat	nstrated by the modified	Neuropathy	Impairment S	Scale+7 (mNIS+		
H. ACKNOWLEDG	EMENT								
Request Complete	ed By (Signature I	Required):				Date	e: / /	<u>!</u>	
			ation of coverage of a m	nedical procedure or ser	vice with the				

any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent

insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.